Hillstream Selected to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
January 11th, 2021
Bridgewater, New Jersey – Hillstream BioPharma, Inc. (“Hillstream”), a clinical- stage biotechnology company leveraging its computational intelligence platform to help identify and develop novel therapeutics for rare cancers, announced today that the company will present at the 2021 BioConnect Virtual Conference hosted by H.C. Wainwright. Registered attendees can access the recorded presentation on-demand (24×7) for the duration of the conference.
|Conference Date:||January 11-14, 2021 (Monday-Thursday)|
|On-Demand Starts:||6:00am ET – Monday, January 11, 2021|
|On-Demand Ends||9:00pm ET- Thursday, January 14, 2021|
Randy Milby, Chief Executive Officer, will highlight the company’s mission of leveraging its computational intelligence platform to help identify and develop novel therapeutics for rare cancers, and the company’s strategy going forward on scientific and corporate fronts. Hillstream will be available for virtual 1:1 meetings both during and after the BioConnect Virtual Conference. Please contact Jennifer K. Zimmons, Ph.D. firstname.lastname@example.org 917.214.3514 for scheduling.
About Hillstream Biopharma, Inc. Hillstream BioPharma, Inc. (the “Company”) is a clinical stage biotechnology company leveraging its computational intelligence platform to help identify and develop novel therapeutics for rare cancers. The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory cytokines directly into the tumor microenvironment. We will work to improve the lives of patients as we rapidly move into the clinic to treat osteosarcoma, small cell lung cancer and other high, unmet-need rare cancers. For more information, please visit www.hillstreambio.com.
Hillstream BioPharma, Inc.
Randy Milby President & CEO
Tel: +1 302.743.2995
Jennifer K. Zimmons, Ph.D.
Investor Relations Zimmons
Tel: +1 917.214.3514
Source: Hillstream BioPharma, Inc.